Benitec Biopharma (BNTC) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Benitec Biopharma (BNTC) is Neutral.

The composite score behind that read is -0.13, weighing +0.09 of bullish evidence against -0.30 bearish.

Benitec Biopharma last closed at $8.87, +1.37% on the session.

Against the IVW growth benchmark the position is +0.57% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

20 graded predictions for BNTC so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Benitec Biopharma in the 24th percentile on return on equity, where 100 is best.

Benitec Biopharma is classified under Health Care / Biotechnology, with a market capitalisation of $305.23M.

StockMap tracks Benitec Biopharma as the 212th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Benitec Biopharma ranks 246th of 381 in the group, against a group median of -0.08.